12-month cannabis use disorder (Table 3) was associated with other substance disorders (OR=6.0–9.3), mood disorders (OR=2.7–5.0), anxiety disorders (OR=1.7–3.7), PTSD (OR=3.8) and personality disorders (OR=3.8–5.0). Lifetime cannabis use disorder (Table 3) was also associated with other substance disorders (OR=6.6–13.4), mood disorders (OR=2.6–3.8), anxiety disorders (OR=2.1–3.2), PTSD (OR=5.0) and personality disorders (OR=4.0–4.7). Across severity levels, 12-month and lifetime cannabis use disorders were associated with other disorders. Further, with few exceptions (12-month Bipolar II, agoraphobia and specific phobia), associations became stronger (i.e., progressively higher odds ratios) as severity of cannabis use disorder increased. For example, ORs of PTSD and 12-month mild, moderate and severe cannabis use disorder were 2.1, 6.2, and 9.5; of nicotine use disorder, 4.8, 7.3, and 10.5; and of borderline personality disorder, 4.0, 4.9, and 8.8. Supplemental Table 1 provides additional comorbidity information, i.e., 12-month and lifetime prevalence of DSM-5 cannabis use disorder (any, mild, moderate, severe) among participants with 12-month or lifetime diagnoses of each disorder in Table 3. Cannabis use disorders had higher prevalence among participants with other disorders than in the total sample. For any 12-month
